Texas Instruments stock price holds near $197 after-hours as TXN earnings loom
27 January 2026
1 min read

Texas Instruments stock price holds near $197 after-hours as TXN earnings loom

New York, January 26, 2026, 19:20 EST — After-hours

Shares of Texas Instruments Incorporated (TXN.O) rose 1.7% to $196.59 on Monday and stayed flat in after-hours trading after the 4 p.m. close. The stock opened at $193.31 and hit an intraday high of $196.94.

Another key moment is just around the corner. The chipmaker is set to report earnings after Tuesday’s close, with investors looking for fresh insight into demand amid swings in industrial and automotive semiconductor markets. Data from Investing.com South Africa shows analysts forecasting earnings of $1.29 per share on revenue near $4.45 billion.

Texas Instruments heads into a busy stretch, wedged between big tech earnings and a Federal Reserve policy decision. The Fed is anticipated to keep rates unchanged, but shifts in its inflation language could unsettle growth stocks, which often react sharply to interest rate signals. 1

Trading volume on Monday picked up, with about 9.2 million Texas Instruments shares changing hands versus the 50-day average of 6.9 million. The stock still sits roughly 11% below its 52-week high set in July, per MarketWatch data. Nvidia and Qualcomm both slipped, while Broadcom pushed higher. 2

Texas Instruments said earlier this month it will stream its Q4 and full-year earnings call on Tuesday at 3:30 p.m. Central. CEO Haviv Ilan, CFO Rafael Lizardi, and investor relations chief Mike Beckman are set to discuss the results and take questions. The company, a major semiconductor manufacturer, supplies analog and embedded processing chips for industrial, automotive, and personal electronics markets. 3

Investors frequently react more to the guidance—the company’s outlook for the next quarter—than to the headline EPS itself. Comments on customer inventories and order patterns can be just as influential as the revenue figures.

Texas Instruments is frequently seen as a crucial indicator for factory and auto production trends. Its analog chips play a vital role in everything from power management to sensors. As a result, any hint of restocking—or a lack thereof—can trigger swift moves in the stock.

After-hours trading on Monday stayed subdued, but that could change in a flash once the release hits. Semiconductor shares tend to spike on even a brief mention of lead times or pricing.

The risk is straightforward: a cautious forecast or margins falling short of expectations could spark renewed doubts about the strength of the industrial demand recovery. If rates rise or risk sentiment sours, that could trigger a broader selloff and ramp up the pressure.

After the U.S. close on January 27, investors will focus on the earnings report, followed soon by the conference call.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
GE Vernova stock rises into earnings week as Wall Street braces for the Fed
Previous Story

GE Vernova stock rises into earnings week as Wall Street braces for the Fed

Rocket Lab stock drops nearly 10% as Neutron timing stays in focus ahead of Feb. 26 results
Next Story

Rocket Lab stock drops nearly 10% as Neutron timing stays in focus ahead of Feb. 26 results

Go toTop